Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difucol Hexamethyl Ether SCHEMBL505203 | 0.77 | CYP1A2 (0.60) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL9170974 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL1402759 | 0.76 | ALDH1A1 (0.79) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL1402344 | 0.75 | CYP1A2 (0.48) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL686849 | 0.74 | CYP1A2 (0.64) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL862161 | 0.74 | ALDH1A1 (0.56) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL10734888 | 0.72 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL12581396 | 0.72 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL2091704 | 0.72 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL9173991 | 0.72 | ALDH1A1 (0.53) | ALDH1A1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10899791-B2 | Method for synthesizing etelcalcetide or salts thereof | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD (TW) | 2021-01-26 | — | — | US | claimed |
| US-20190100554-A1 | METHOD FOR SYNTHESIZING ETELCALCETIDE OR SALTS THEREOF | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD (TW) | 2019-04-04 | — | — | US | claimed |
| EP-2123695-B1 | METAL THIETANE COMPOUND, POLYMERIZABLE COMPOSITION COMPRISING THE COMPOUND, RESIN, AND USE OF THE RESIN | MITSUI CHEMICALS INC (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-10899791-B2 | Method for synthesizing etelcalcetide or salts thereof | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD (TW) | 2021-01-26 | — | — | US | disclosed |
| US-20190100554-A1 | METHOD FOR SYNTHESIZING ETELCALCETIDE OR SALTS THEREOF | CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO. LTD (TW) | 2019-04-04 | — | — | US | disclosed |
| EP-2314637-B1 | COMPOSITION, POLYMERIZABLE COMPOSITION, RESIN, OPTICAL COMPONENT, AND PRODUCTION METHOD OF COMPOSITION | MITSUI CHEMICALS INC (JP) | 2017-07-12 | — | — | EP | disclosed |
| EP-2230271-B1 | ADDITIVE FOR POLYMERIZABLE COMPOSITION, POLYMERIZABLE COMPOSITION CONTAINING THE SAME, AND USE OF THE POLYMERIZABLE COMPOSITION | MITSUI CHEMICALS INC (JP) | 2016-09-07 | — | — | EP | disclosed |
| EP-2982706-A1 | ADDITIVE FOR POLYMERIZABLE COMPOSITION, POLYMERIZABLE COMPOSITION CONTAINING THE SAME, AND USE OF THE POLYMERIZABLE COMPOSITION | Mitsui Chemicals, Inc. (JP) | 2016-02-10 | — | — | EP | disclosed |
| EP-2292597-B1 | METAL COMPOUND, POLYMERIZABLE COMPOSITION CONTAINING THE SAME, RESIN, METHOD FOR PRODUCING THE RESIN AND USE OF THE RESIN | MITSUI CHEMICALS INC (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-8697889-B2 | Metal compound, polymerizable composition containing the same, resin, method for producing the resin, and use of the resin | MITSUI CHEMICALS, INC. (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-1813639-B1 | METAL-CONTAINING COMPOUND AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2014-03-12 | — | — | EP | disclosed |
| US-20070191615-A1 | Polymerizable compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1813639-A1 | METAL-CONTAINING COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1731547-A1 | POLYMERIZABLE COMPOUNDS AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| US-5420128-A | Pyrimidine derivatives, method of manufacturing the same, and androgen inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-30 | — | — | US | disclosed |
| EP-0503099-A1 | PYRIMIDINE DERIVATIVE, PRODUCTION THEREOF, AND ANDROGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885CA12 1998/4885CA1 3493/4885 |
| US-20190100554-A1 | METHOD FOR SYNTHESIZING ETELCALCETIDE OR SALTS THEREOF | PTMS, PTH1R, CYP24A1 | ALDH1A1 2583/4885CA12 1752/4885CA1 915/4885 |
| US-20070191615-A1 | Polymerizable compound and use thereof | RPS4X, MLX, RPS4Y1 | ALDH1A1 3156/4885CA12 3194/4885CA1 1618/4885 |
| US-10899791-B2 | Method for synthesizing etelcalcetide or salts thereof | PTMS, PTH1R, CYP24A1 | ALDH1A1 2583/4885CA12 1752/4885CA1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.